EXAMINE THIS REPORT ON HEMGENIX

Number of eligible people: CDEC discussed the uncertainty in the amount of sufferers with moderately significant to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some clients that are categorized as possessing gentle or moderate illness might have a serious bleeding ph